Despite recent research which more and more stresses the importance of osteocytes in regulating bone and systemic mineral metabolism, current molecular and functional knowledge of osteocyte properties are still incomplete, mostly due to limited availability of in vitro models.
Introduction
Osteocytes are the most abundant cell type in bone, derived from progressive transformation of a subpopulation of committed osteoblasts, which progressively embed in newly formed matrix. During embedding, committed osteoblasts change phenotype according to an active program dictated by a specific pattern of gene expression, that leads to regulated polarised formation of multiple dendrites and expression of specific proteins, relevant to bone mass regulation, phosphate homeostasis, hypoxia resistance and cytoskeletal organisation (Bonewald, 2011) .
The cell body of mature osteocytes is contained in bone lacunae and the extended branched dendrites reside in tiny channels called canaliculi, forming an intricate web that makes multiple contacts not only with other osteocytes, but also with other bone cell types, bone marrow, and blood vessels. Through the interstitial fluid contained in lacunae and canaliculi, osteocytes are also ultimately connected to the circulating system, therefore they can influence not only local but also systemic events, and vice versa, their behaviour can be regulated by both local and systemic changes (Cheng and Hulley, 2010) .
Given the central role in bone and system physiology, numerous research efforts have been carried out to reveal the biological properties of osteocytes and understand their contribution to health and disease states. In recent years, a number of technical improvements, such as the generation of tissue-and cell-specific transgenic animals, the use of powerful microscopy techniques and of highthroughput molecular screening, have favoured these analyses, providing novel information on osteocytespecific molecular expression patterns and identifying key regulators of osteocyte function (Paic et al., 2009; Dallas and Bonewald, 2010) .
The difficulty of culturing osteocytes remains a current issue, due to the high level of differentiation of this cell type. Therefore, novel in vitro methodologies could enhance the possibilities of studying these cells and improve knowledge of osteocyte biology. To be widely usable, such methods should be easy to reproduce, would not require special instrumentation or very long times to reach cell maturation.
Since osteocytes derive from differentiation of committed osteoblasts, this process has been largely studied in vitro, where osteoblast differentiation can be induced by matrix scaffolds (Boukhechba et al., 2009; Krishnan et al., 2010 ) and a variety of substances. Among molecules D Mattinzoli et al. ATRA-induced osteocyte differentiation that are known to influence osteoblast differentiation, such as parathyroid hormone (Tian et al., 2011) , oestrogens (Mizutani et al., 1998) , Bone Morphogenetic Proteins (Suzawa et al., 1999) , and Fibroblast Growth Factors (Marie, 2012) , melatonin and retinoic acid have been extensively studied and are known to play important roles in bone physiology and physiopathology. Melatonin is an indoleamine primarily secreted by the pineal gland, but also synthesised in other organs, such as the retina, the gastrointestinal tract, and noteworthy, the bone marrow. It has a regulatory role in several physiological processes, from hypothalamic control of circadian rhythms to modulation of the immune system (Sánchez-Barceló et al., 2010) . Human osteoblasts express melatonin receptors, and numerous experiments have concordantly shown that pharmacological, micromolar doses of melatonin increase osteoblast proliferation, alkaline phosphatase activity, expression of type I collagen, osteopontin, bone sialoprotein, osteocalcin, and mineralised matrix formation (Roth et al., 1999) .
All-trans retinoic acid (ATRA) is an active metabolic product of vitamin A, and a master regulator of gene expression. It exerts its effects on gene transcription by binding to nuclear retinoic acid receptors (RARs). RARs bind to DNA as heterodimers with the retinoid X receptors (RXRs), ultimately leading to modulation of retinoic acid-responsive target genes (Ross et al., 2000) . Though in vitro analyses of retinoic acid effects on osteoblasts have reported contradicting results in terms of maturation and mineralisation (Song et al., 2005; Cohen-Tanugi and Forest, 1998) , both melatonin and ATRA seem to accelerate maturation of the murine pre-osteoblast MC3T3-E1 cell line (Roth et al., 1999; Nagasawa et al., 2005) .
This cell line has been extensively analysed and appears to be a very good model of bone development because its growth, in the presence of ascorbic acid and glycerol phosphate, invariably passes through three distinct stages of proliferation, differentiation and mineralisation, with well-defined stage-specific gene expression patterns (Quarles et al., 1992) .
Ascorbic acid and glycerol phosphate have also been shown to favour and accelerate deposition of calcified extracellular matrix in primary rodent osteoblasts (Stangenberg et al, 2005) , which can be obtained in sufficient numbers by well-established isolation procedures.
Here we describe that addition of ATRA to MC3T3-E1 cells, or to primary cells isolated from mouse calvaria, if applied at a precise maturation stage on cells plated at a defined density, induces a phenotype switch that results in a homogeneous population of ramified cells. The osteocyte nature of these cells is confirmed by extensive morphological and molecular characterisation, and the effect seems highly ATRA-specific because it is not obtained by application of melatonin in the same conditions.
Materials and Methods

MC3T3-E1 cell line
The MC3T3-E1 cell line, subclone 4 (Wang et al., 1999) , a pre-osteoblast cell line established from normal newborn mouse calvaria, was obtained from the American Type Culture Collection (ATCC) (LGC Standards, Sesto San Giovanni, Milan, Italy). 400,000 cells were initially plated in a 75 cm 2 flask, and were cultivated in alpha-MEM medium (Invitrogen, Milan, Italy), supplemented with 10 % FBS (Sigma-Aldrich, Milan, Italy) and 1 % streptomycin/penicillin (Sigma-Aldrich). When cells reached 80 % confluence, 50 µg/mL ascorbic acid and 3 mM glycerol 2-phosphate disodium salt hydrate (SigmaAldrich) were added and the medium was changed every other day.
After 5 days of incubation with ascorbic acid/glycerol phosphate (AA/GP), cells were trypsinised and re-seeded in 25 cm 2 flasks, according to their subsequent utilisation. A first group was plated at a density of 10,000 cells/cm 2 and continued to be cultivated in the same conditions, namely basal medium plus AA/GP, whereas melatonin (Sigma-Aldrich) was added to basal medium plus AA/GP in a second group of cells, plated at 10,000 cells/cm 2 as well. Retinoic acid (All Trans Retinoic Acid, ATRA, from Sigma-Aldrich) was added to basal medium plus AA/GP in a third group of cells.
In ATRA-treated cells, we found that the initial cell density was relevant to the optimal development of cell processes and intercellular contacts. While a starting density of 10,000 cells/cm 2 was too high, because it impaired proper development of cell processes, too low cell numbers resulted in premature cell death, due to the absence of intercellular contacts. After these experiments, the optimal density was set at 5000 cells/cm 2 . 
Melatonin and retinoic acid treatment
To optimise culture conditions, melatonin and ATRA dosedependent (1 µM, 10 µM, 20 µM, 50 µM and 100 µM) and time-dependent preliminary analyses were carried out.
Based on these first experiments, 50 µM melatonin and 10 µM ATRA were used in all subsequent studies conducted on MC3T3-E1 cells. Morphological changes started after 4 days of treatment.
In primary cells, 1 µM ATRA did not have any effect, but 10 µM ATRA resulted in too rapid aging and cell death, and optimal ATRA concentration in our hands was 5 µM. Morphological changes started after 48 h of treatment.
All experiments using ATRA were conducted in a darkened room to prevent ATRA inactivation. Eindhoven, The Netherlands). All reagents and grids for electron microscopy were from Electron Microscopy Sciences (Società Italiana Chimici, Rome, Italy).
Microscopy and immunofluorescence
For atomic force microscopy (AFM), cells grown on plastic coverslips were fixed with 2.5 % glutaraldehyde in cacodylate buffer 0.1 M for 10 min at room temperature, washed three times in cacodylate buffer, partially dehydrated (up to 70 %) and allowed to dry. Characterisation of cell topography was performed using the A100-CL AFM (A.P.E. Research, Area Science Park, Trieste, Italy) in NonContact Mode, by silicon nitride cantilevers with spring constant of 40 N/m and curvature radius of 10 nm (NSC15 type, MikroMasch, Tallinn, Estonia).
For indirect immunofluorescence (Li et al., 2011) , cells were alternatively fixed in 4 % paraformaldehyde or cold acetone, depending on the primary antibody to be applied. 
Cell proliferation assay
To quantify proliferating cells, we used a 5-bromo-2-deoxyuridine (BrdU) cell proliferation assay kit (Cell Signalling Technology, Euro Clone, Milan, Italy), according to the manufacturer's instructions.
Briefly, MC3T3-E1 cells after 8 days of treatment and primary cells after 4 days of treatment were plated (8 replicates per each condition) at the above described densities (namely, 10.000 cells/cm 2 for all cell groups but ATRA-treated MC3T3-E1, seeded at 5000 cells/cm 2 ) in 96-well plates (one plate was used per each time point) and left to adhere for 24 h. Then cell medium was replaced by medium containing 10 µM BrdU.
After 24 and 48 h, medium was removed and replaced by the fixing/denaturing solution provided by the kit, kept at room temperature for 30 min, and then removed. Cells were subsequently incubated with the primary mouse anti-
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BrdU antibody at room temperature for 1 h, followed by washing and application of the secondary HRP (horseradish peroxidase)-conjugated anti-mouse IgG. After washing, 3,3',5,5'-Tetramethylbenzidine (TMB) substrate was added to reveal peroxidase activity, followed by the TMB Stop solution included in the kit. Absorbance was read at 450 nm immediately after adding the Stop solution.
Alizarin red staining and extraction methods
Alizarin red staining solution (1 mg/mL, pH 5.5, SigmaAldrich) was added to ethanol-fixed cells (70 % ethanol for 10 min), and washed with tap water after 30 min. After images were taken, cells were destained by 60 % perchloric acid at 4 °C. Optical density of the supernatant was evaluated by spectrophotometry at 450 nm wavelength.
To normalise values for cell number, Janus green whole cell stain was then added to the cell preparation for 10 min. Cells were washed with tap water and the staining was evaluated by spectrophotometry at 615 nm wavelength. Cells were seeded at the concentrations described above and 3 to 5 replicates were studied per each treatment and time point.
Alkaline phosphatase 0.1 mg fast red/naphthol solution was added to 4 % paraformaldehyde-fixed cells for 30 min, and results were evaluated by light microscopy. As a positive control, the method was applied to normal mouse kidney sections, where proximal tubules and the Bowman's capsule are known to contain the enzyme. Negative controls were performed after blocking alkaline phosphatase with 5 mM levamisole, as described (Goldstein et al., 1980) . Cells were seeded at the concentrations described above and 3 replicates were analysed per each treatment and each time point.
ELISA tests
Osteocalcin and FGF23 levels in the supernatants were evaluated by ELISA (mouse osteocalcin ELISA kit, Biomedical Technologies, Stoughton, MA, USA; and mouse FGF23 ELISA kit, Immutopics International, Pantec, Torino, Italy), according to the manufacturer's instructions. The Osteocalcin ELISA test has a sensitivity of 1 ng/mL, with intra-assay variation of 6 % and interassay variation of 8 %. Mouse FGF23 ELISA has a sensitivity of 4 pg/mL, intra-assay variation of 6.2 % and inter-assay variation of 5.9 %. ELISA tests were conducted on MC3T3-E1 cells (3 replicates per treatment condition and each time point).
mRNA extraction and RT-PCR (Real Time RT-PCR)
Total RNA was extracted by Trizol (Invitrogen) and precipitated by chloroform-isopropil alcohol, washed in 75 % ethanol, resuspended in nuclease free-water, then treated with DNase, resuspended, and quantified by spectrophotometry. cDNA was prepared from 1 µg RNA using the iScript Select cDNA Synthesis Kit and oligo(dt)20 primers (Bio-Rad, Segrate, Milan, Italy).
Multiple Real Time RT-PCR data of molecules related to bone maturation were obtained using the mouse Osteogenesis Array Kit (SABiosciences, Qiagen, Milan, Italy), according to the manufacturer's instructions. For these experiments, RNA was obtained from 3 replicates (three 25 cm 2 flasks) per each condition at one time point. Specifically, MC3T3-E1 cells were studied at 15 days, whereas primary cells were studied at 7 days of treatment.
Part of the MC3T3-E1 mRNA was separately used to evaluate FGF23 and OPG expression, with the following primers: FGF23: forward 5'GAT CCC CAC CTC AGT TCT CA3'; reverse 5'CCG GAT AGG CTC TAG CAG TG3'; OPG: forward 5'GCC ACG CAA AAG TGT GGA AT3'; reverse 5'TTT GGT CCC AGG CAA ACT GT3'; data were normalised against the expression of GAPDH (forward primer 5'GGT ATC GTG GAA GGA CTC ATG A3'; reverse primer 5'GGC CAT CCA CAG TCT TCT G3'). After assessment of primer specificity by RT-PCR (not shown), Real Time RT-PCR was run with iQ Sybr Green Supermix (Bio-Rad) on a MyIQ instrument (BioRad), and data were analysed by the IQ5 Bio-Rad Software.
Protein isolation and Western blot
After cell lysis in RIPA buffer [25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 % NP-40 (nonyl phenoxy polyethoxyl ethanol), 1 % sodium deoxycholate, 0.1 % SDS (sodium dodecyl sulphate)], protein extracts were separated on a SDS-PAGE and transferred by electroblotting on a PVDF membrane (ImmunBlot PVDF membrane, Bio-Rad). After blocking, each membrane was incubated with the primary antibody, followed by the anti-mouse or anti-rabbit HRPconjugated secondary antibody, and positive reaction products were identified by chemiluminescence (BM Chemiluminescence Western Blotting Kit, Roche, Monza, Italy). Loading controls were conducted with antibodies directed against alpha-tubulin (Abcam), beta-actin (SigmaAldrich) and cofilin (Abcam). Negative controls were performed by loading buffer instead of protein extracts or by pre-incubating the primary antibody with a blocking peptide (Fig. 1) .
Images were digitally acquired by Chemidoc XRS instrument (Bio-Rad) and analysed by Quantity One software (Bio-Rad).
In-cell ELISA
To get quantification of protein expression data, we used the In-Cell ELISA colorimetric detection kit (Thermo Scientific, Euroclone, Milan, Italy), according to the manufacturer's instructions.
To this purpose, 3 replicates of each cell type were plated at the same seeding densities as described above on a 96-well plate. After 4 % buffered paraformaldehyde fixation, cells were sequentially incubated with permeabilisation buffer, quenching solution and blocking buffer. The primary antibody was then added, followed by the HRPconjugated secondary antibody and TMB substrate. The reaction was stopped after 15 min with the TMB stop solution and absorbance was immediately measured at 450 nm wavelength. After washing, Janus green whole-cell stain was added for 5 min. Careful washing was followed by addition of elution buffer and absorbance was read at 615 nm. Replicate background measurements were
subtracted from all 450 nm measures. The resulting A450 values were then normalised to the A615 values to account for differences in cell number.
Statistical analyses
Experiments were conducted on 3 to 8 replicates per each condition and time point, as specified above. Data were expressed as mean ± standard deviation (SD), and Student's t-test was applied to determine significance (p < 0.05). For Real Time RT-PCR, relative RNA abundance was determined using the comparative Ct method (Livak and Schmittgen, 2001) .
Real Time PCR Array data analysis was conducted by using the online software resource at: http://pcrdataanalysis. sabiosciences.com/pcr/arrayanalysis.php. For MC3T3-E1 cells, fold change of melatonin (group 1) and ATRA (group 2) results were compared to AA/GP cells taken as control group. Results from primary cells were evaluated separately, and fold change of ATRA data (group 1) were compared to AA/GP expression data (control group).
Fold change error bars, calculated by the online software, represent the standard deviation (σ) of the fold change (FC), according to the following formula: σ FC = FC * ln2 * sqrt(σ x 2 /n x +σ y 2 /n y ). P values were calculated based on a Student's t-test of the replicate 2^(-Delta Ct) values for each gene in the control group and treatment groups, and p values <0.05 were considered significant.
Results
Cell morphology
MC3T3-E1 cells observed by light microscopy after 4 days incubation with AA/GP displayed classical cuboidal appearance (Fig. 2a,b) , typical of osteoblasts, that did not change with time. 50 µM melatonin rapidly increased cell density. Though the majority of cells conserved a cuboidal appearance, sparse ramified cells appeared from day 8 (Fig. 2c,d ).
AA/GP treated primary cells had mostly cobblestonelike features (Fig. 2e) , with interspersed ramified cells (Fig.  2f) .
Addition of ATRA (10 µM in MC3T3-E1 cells and 5 µM in primary cells) completely changed the morphology of both cell populations; as soon as 4 days in the cell line and 2 days in primary cells, ramifications extended from the cell body and progressively increased in number and complexity (Fig. 2g-j) .
By AFM -which provides high resolution images of the cell surface in the absence of alterations coming from additional manipulation/staining procedures -the complexity of cell ramifications produced by ATRA treatment was more evident (Fig. 3a) , and it was possible to appreciate their non-homogenous conformation, characterised by periodical enlargements (Fig. 3b-d) ; secondary processes departed from primary processes, and ramifications from neighbour cells frequently interconnected.
Staining of filamentous actin by rhodamine-labelled phalloidin highlighted the differences among treatments, because cell processes of ATRA-treated cells were labelled by phalloidin (Fig. 3e-f) . In AA/GP-and melatonin-treated cobblestone cells actin was organised in stress fibres and appeared reinforced at the cell periphery, emphasising the rounded shape (Fig. 3g) . In primary cells, actin staining also evidenced the presence of sparse ramified cells among the cobblestone ones (Fig. 3h) .
TEM allowed further comparison and evaluation of morphological details. After 15 days of treatment, MC3T3-E1 cells incubated either with AA/GP or melatonin had particularly developed Golgi apparatus and endoplasmic reticulum (Fig. 4a,b) . Numerous rounded areas of collagen accumulation occupied the cell body (Fig.  4a-c ) and large numbers of collagen fibres were also clearly detectable in the extracellular space (Fig. 4d) . MC3T3-E1 cells treated for 15 days with ATRA displayed ramified projections that were laterally interacting with other ramifications or with the cell body of neighbour cells (Fig.  4e-h ). Lateral adhesions were mostly made by adherens junctions. No intracellular collagen accumulation was found, nor was extracellular matrix deposition detectable.
Cell proliferation
Incorporation of BrdU was higher in melatonin-treated MC3T3-E1 cells than in AA/GP cells, though the difference was not statistically significant. ATRA treatment decreased significantly cell proliferation in both the cell line and primary cells (Fig. 5) .
Matrix production and mineralisation
Matrix mineralisation, as assessed by alizarin red staining, was most abundant in melatonin-treated cells, whereas it was completely absent in ATRA-incubated cells (Fig.  6) . The result was confirmed also by spectrophotometry measurement of alizarin red extracted from all cell types, which was minimal in ATRA-treated cells, and the highest in melatonin-incubated cells.
Alkaline Phosphatase was barely detectable in cells treated with ATRA (Fig 7a,d) as compared with cells incubated with melatonin or AA/GP (Fig 7b,e) . mRNA was concordantly lower in ATRA treated cells (Fig. 7c,f) .
Collagen type I immunofluorescence revealed the presence of abundant collagen fibrils inside and outside MC3T3-E1 cells treated with AA/GP and melatonin (Fig.  8a,b) . ATRA limited the expression of collagen type I to the intracellular compartment only, in a perinuclear location (Fig. 8c) . In-cell ELISA showed constant expression levels of collagen type I in AA/GP and melatonin-treated cells, whereas the amount of collagen progressively decreased with time in ATRA-incubated cells (Fig. 8d) . The mRNA of collagen type I alpha1 chain was greatly reduced in ATRAtreated cells as compared to AA/GP and melatonin-treated cells (Fig. 8e) .
Osteocalcin release into the supernatant of melatonintreated cells progressively increased with time, whereas it was almost absent from the medium collected from ATRA-treated cells (Fig. 9 ).
Other markers
Osteoprotegerin was diffusely expressed by AA/GP-treated cells, whereas only a few ATRA-treated cells were positive (Fig. 10) . Connexin 43 was detectable by immunofluorescence in all groups of cells ( Fig. 11a-d) at any time point. In ramified cells the molecule was observed along and at the tip of cell processes (Fig. 11b-d) . In-Cell ELISA (Fig. 11e) and Western Blot (Fig. 11f) showed the presence of the protein in almost equal amounts in all cell types, supporting the presence of differences only in its subcellular distribution.
E11/gp38, assessed by immunofluorescence and western blot, was expressed by the majority of MC3T3-E1 cells after 5 days of ATRA incubation, and decreased after 10 days (Fig. 12a-c) . In primary cells, it appeared after 2 days of ATRA treatment and was almost undetectable at 7 days. The protein was not expressed at any time by AA/ GP-treated MC3T3-E1 cells (Fig. 12c,d ), whereas sparse ramified cells, found either among melatonin-treated MC3T3-E1 cells (Fig. 12c,e) and AA/GP-treated primary osteoblasts, were mildly positive.
Sclerostin mRNA and protein were consistently expressed only by ATRA-treated cells (Fig. 13a-f) . Immunostaining revealed intense cytoplasmic expression and the presence of positive dots along cell processes.
Differentially expressed genes
By immunofluorescence, a strong FGF23 positivity was detectable only in ATRA-treated cells (Fig. 14a-k) . By Western Blot FGF23, barely expressed by cells incubated for 5 days with AA/GP, showed a clear band in ATRAtreated cells, and a mild expression in melatonin-incubated cells (Fig. 15a) . The amount of secreted FGF23, as detected by ELISA-test conducted on the supernatant, increased with time in all cell types, and was mostly abundant in ATRA-treated cells (Fig. 15b) . FGF23 mRNA, assessed by Real Time RT-PCR, showed the highest expression in ATRA-treated MC3T3-E1 cells at 5 days of incubation (Fig. 15c) .
Compared to AA/GP and melatonin, ATRA-treated cells displayed mRNA upregulation of several bone morphogenetic proteins, such as Bmp2 (Fig. 16a) , and metalloproteinases.
Finally, ATRA-treated cells disclosed increased expression of a series of osteocyte-specific molecules, such as Dmp1, Phex, and Tuft1 ( Fig. 16b-d) . In parallel, typical markers of the osteoblasts, such as Runx2, were downregulated (Fig. 16e) .
Discussion
Investigation of osteocyte biology has always suffered from the limited availability of in vitro models and, until recently, from the difficulty of characterising these cells by reliable specific markers. For these reasons, osteoblasts were used as surrogate cells over a long period before the osteocyte-like cell line MLO-Y4 (Bonewald, 1999) was made available. Undoubtedly, this cell line remains the best and most widely used in vitro osteocyte model.
Isolation and culture of primary osteocytes, first obtained from chick bones (Van der Plas and Nijweide, 1992; Nijweide et al., 2003) , and subsequently from rat calvaria (Gu et al., 2006) , represented a major breakthrough in the field; primary cells better resemble the in vivo situation, but their isolation generates only a small number of cells per procedure, and cell purity relies to a large extent on individual expertise, therefore the method is currently used only by a limited number of laboratories.
More recently, mature osteocytes have been obtained by inducing terminal differentiation of osteoblasts by progressive embedding in a three-dimensional mineralised matrix (Boukhechba et al., 2009; Krishnan et al., 2010) , that constitutes a more physiological environment but is
ATRA-induced osteocyte differentiation , and 20 days = T20). Release of osteocalcin is similar (<0.25 ng/ mL) at the first day of treatment, then progressively increases with melatonin incubation, whereas it is almost abolished by ATRA. Asterisks indicate significant differences: * = p < 0.05; ** = p < 0.01. an obstacle to subsequent research applications. It is true that matrix mineralisation (Irie et al., 2008) , as well as low oxygen tension (Hirao et al., 2007) , are physiological triggers of osteocyte maturation. However, a methodology avoiding these two conditions could increase feasibility and extend the use of the cells. Our proposed method, that consists of adding retinoic acid to osteoblasts derived from initial maturation of the MC3T3-E1 cell line or to primary osteoblasts, is simple and highly reproducible.
Among molecules recently proposed to induce an osteocyte-like phenotype, the multifunctional cytokine Oncostatin M has to be stably transfected by lentiviral particles to achieve complete osteocyte differentiation from the rat osteosarcoma OSRGA cell line and from primary rat calvaria cells (Brounais et al., 2009) . Also, mature osteocytes have been obtained by adding fibroblast growth factor-2 (FGF-2) to MC4 cells (Gupta et al., 2010) . Compared to these methods, retinoic acid addition is simpler than transfection and less expensive than FGF2.
With a series of preliminary experiments we determined that the starting cell number is a critical factor, conditioning proper formation of multiple dendrites and intercellular contacts. A too high plating cell density affects complexity and extension of cell processes, whereas too low numbers result in loss of intercellular adhesions, leading to cell suffering and death. Similar results were observed in other cell types, where cell density profoundly influenced the phenotype (Bauer et al., 2008; Sessarego et al., 2008; Turncliff et al., 2006) . Our method is highly reproducible, in both primary cells and the cell line; murine MC3T3-E1 cells, particularly the clones able to produce mineralised extracellular matrix, are largely in use and unanimously considered a biologically relevant model of osteoblast development because their maturation has numerous molecular similarities with the process in vivo (Quarles et al., 1992) . Importantly, when the method is applied to primary cells, adjustment of ATRA dosage and daily monitoring of cell morphology are highly advised, because of the variability incidental to primary cells and the higher sensitivity to ATRA, as compared to the cell line.
It is well known that one of the most important ongoing changes during osteoblast transformation into osteocytes is the change of shape, from a polygonal cell to a ramified cell type, which is first detectable at the stage of osteoid osteocyte (Dallas and Bonewald, 2010) . ATRA-incubated cells display ramifications as soon as after two days of treatment. As it occurs in primary osteocytes (Tanaka-Kamioka et al., 1998) , dendrites are highly enriched in actin filaments. The peculiar morphology of these ramifications, with periodical enlargements, highly resembles that of other highly ramified cells (Wang et al., 2011) , such as neuronal cells, when observed by AFM or scanning electron microscopy.
Connexin43 (Cx43) is the most abundant connexin in bone cells. Multiple lines of evidence have established its important role in function and survival of both osteoblasts and osteocytes (Stains et al., 2003) , which is in line with our results, showing Cx43 in all groups of cells, independent of treatment. The extension of dendrites produced by ATRA incubation affects the location of Cx43, that can be observed along and at the tip of cell processes. We were not able to identify complete gap junctions in any of our cell types by electron microscopy, and we did not find published data displaying by electron microscopy complete gap junctions in cultured bone cells. However, it is well known that connexons can function as gap junction hemichannels, being active without pairing with apposing connexons (Civitelli, 2008) , and in in vitro conditions this configuration could be sufficient to maintain proper intercellular communication and response.
Since its first characterisation and cloning, E11/ gp38 (also known as podoplanin, T1A, GP36, GP40, OTS8, AGGRUS, and PA2.26) was selectively detected in osteocytes and pre-osteocytes, where its role can be relevant to development of cell dendrites (Zhang et al., 2006) . Accordingly, we did not observe E11/gp38 in preosteoblasts and AA/GP incubated cells, though we did find a mild positivity in melatonin-treated cells and in the sparse ramified cells that are present among primary osteoblasts. In agreement with its predicted function, E11/ gp38 peaks at the beginning of ATRA treatment, when the development of cell processes is particularly active, and progressively declines during further cell maturation.
In parallel, extracellular matrix deposition and mineralisation are rapidly abolished in ATRA-incubated cells, as shown by the absence of extracellular collagen fibres and negativity of alizarin red staining. These events are confirmed by decrease of alkaline phosphatase and collagen type I, and progressive reduction of osteocalcin release. Furthermore, ATRA reduces osteoprotegerin, an important inhibitor of osteoclastogenesis and bone resorption (Udagawa et al., 2000) , and the osteoblastspecific transcription factor Runx2 (Prince et al., 2001) .
It is well known that osteocytes do not produce calcified matrix. Additionally, osteocytogenesis is now considered an active invasive process, during which degradation and remodelling of extracellular matrix are needed by osteocytes to enter the bone, and to form and maintain the extracellular environment of lacunae and canaliculi (Karsdal et al., 2004; Qing and Bonewald, 2009 ). According to these observations, our findings show increased mRNA levels of several matrix metalloproteinases and bone morphogenetic proteins in ATRA-treated cells.
Along this line of evidence, ATRA induces other wellknown osteocyte markers, such as Dmp1, Phex, Tuft1 and, most notably, sclerostin.
Dmp1 is a major regulator of mineralisation and has been shown to play a central role in the transition of osteoblasts/preosteocytes to osteocytes (Rios et al, 2005) . Phex (PHosphate-regulating Endopeptidase homolog X-linked), whose mutations in humans underlie X-linked hypophosphatemia, is a glycoprotein involved in the regulation of bone mineralisation. Interestingly, Phex deletion in mice causes a hypophosphatemic phenotype identical to that of Dmp1 null mice (Yuan et al., 2008) . Tuft1, which is induced in response to hypoxia, is likely to be relevant to osteocyte survival in the microenvironment of the bone lacunae (Leiser et al., 2011) .
It is our opinion that the strong expression of sclerostin by ATRA-treated cells further supports the mature D Mattinzoli et al. ATRA-induced osteocyte differentiation osteocyte phenotype induced by retinoic acid. In fact, differently from sclerostin mRNA, which is found in many tissues, especially during embryogenesis, in vivo expression of the protein sclerostin has been reported only in osteocytes, in both adult murine and human bone (Poole et al., 2005) . Sclerostin mRNA is increased in cultured osteoblasts after bone morphogenetic protein (Sutherland et al., 2004) and FGF2 stimulation (Gupta et al., 2010) , and here we show a strong expression of both sclerostin mRNA and protein only in ATRA-treated cells. Finally, ATRA-incubated cells display large amounts of FGF23, which is one of the most studied osteocyte products, because of its pivotal role in phosphate homeostasis (Yoshiko et al., 2007) . According to the literature, FGF23 is also produced by osteoblasts (Strom and Jüppner, 2008) . Instead, our data, showing no evidence of intracellular protein in AA/GP-incubated cells, and minimal presence in melatonin-treated cells, suggest only a mild production of this factor by mature osteoblasts. As it occurs in vivo, where the molecule is released into the circulation (Strom and Jüppner, 2008; Yoshiko et al., 2007) , FGF23 is released by our cells into the supernatant. Concordant to the mRNA and protein results, the largest FGF23 amounts can be detected in the supernatant of cells incubated with ATRA. Further studies aimed at investigating the functional role of FGF23 and sclerostin in osteocytes will be facilitated by the endogenous production of these molecules in ATRA-treated cells.
In summary, our findings seem to demonstrate that treatment with retinoic acid generates a homogeneous population of mature osteocytes from the MC3T3-E1 cell line and from primary calvaria cells. Compared to other methods, our protocol seems to present several advantages, primarily the simple application and the high reproducibility. The process of osteocyte maturation can be studied in adequate numbers of cells from the initial spreading of processes through several steps that occur in a 10-day frame. As a further advantage, mature osteocytes are obtained in complete absence of surrounding mineralised matrix, allowing the application of unlimited molecular and functional assays.
